![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 29, 2021 5:12:33 PM
Nov. 29, 2021 2:34 PM ETQualigen Therapeutics, Inc. (QLGN), PTPIBy: Jonathan M Block, SA News Editor1 Comment
?
Vertigo3d/E+ via Getty Images
Microcaps Petros Pharmaceuticals (PTPI +104.3%) and Qualigen Therapeutics (QLGN +24.4%) are among the best performing biotechs today as discussion of the companies accelerates on social media and potential short squeezes taking place.
Message volume on Stocktwits for Petros is up 94% more than average. Stock volume in Petros, as of 2:30 PM, is ~201.6M shares. Average daily volume is 6.6M shares.
By comparison, Qualigen is seeing a more modest upswing. Volume as of 2:30 PM is ~35.8M shares. Average daily volume is ~5.3M shares.
Petros shares surged last week after announcing its annual shareholder meeting for next month.
Now Read: Qualigen Therapeutics EPS beats by $0.11, misses on revenue
Recent QLGN News
- Lifecore Biomedical Announces Cooperation Agreement with 22NW • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:00:18 PM
- Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination • GlobeNewswire Inc. • 05/30/2024 08:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/14/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/04/2024 12:59:19 AM
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:30:40 PM
- Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 07:16:19 PM
- Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer • GlobeNewswire Inc. • 10/23/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 12:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:15:36 PM
- Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 • GlobeNewswire Inc. • 09/27/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:18 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:15:06 PM
- Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 08/17/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 02:04:16 PM
- Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 • GlobeNewswire Inc. • 08/15/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:16:09 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM